Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. [electronic resource]
Producer: 20130927Description: 1838-51 p. digitalISSN:- 1557-3265
- ATP Binding Cassette Transporter, Subfamily B -- genetics
- ATP Binding Cassette Transporter, Subfamily G, Member 2
- ATP-Binding Cassette Transporters -- genetics
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Cytarabine -- administration & dosage
- Etoposide -- administration & dosage
- Female
- Gene Expression Regulation, Leukemic -- drug effects
- Humans
- Hydroxamic Acids -- administration & dosage
- Karyotype
- Leukemia, Myeloid, Acute -- drug therapy
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Proteins -- genetics
- Recurrence
- Translational Research, Biomedical
- Treatment Outcome
- Tumor Necrosis Factor Decoy Receptors -- genetics
- Vorinostat
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.